US FDA asks firms to check quality of glass drug vials
This article was originally published in SRA
The US Food and Drug Administration has expressed concern over several recent incidents of injectable drugs, filled in small-volume glass vials, being recalled due to the formation of glass lamellae (ie glass fragments). The agency is asking manufacturers of these products to re-examine their supplier quality management programme with glass vial manufacturers to prevent such incidents1.
You may also be interested in...
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.
Based on its experience of reviewing tools used by companies for additional risk minimization, the European Medicines Agency is planning to update its guidance on this topic with more information on how these tools can be better employed.